The U.S. prescription digital therapeutics market size accounted for USD 1.64 billion in 2025 and is predicted to increase from USD 2.01 billion in 2026 to approximately USD 12.28 billion by 2035, expanding at a CAGR of 22.30% from 2026 to 2035. PDTs provide a scalable tool to tackle a rising requirement for psychiatric treatment. These therapies offer safe, non-drug substitutes for hard-to-treat conditions such as substance use disorders, major depressive disorder, ADHD, and long-term insomnia, which drives the growth of the market.
Prescription digital therapeutics (PDTs) are software-driven treatments intended to prevent, manage, or treat a health disorder or disease. This type of therapy (PDTs) is an FDA-authorized treatment delivered via mobile devices that addresses the behavioral dimensions of major diseases and conditions and also helps address provider limitations and reduce economic impacts. This technology provides patients with supportive tools and features such as medication reminders, dosing instructions, tracking, educational content, and symptom tracking. Digital therapeutics are recognized as healthcare devices and are subject to worldwide recognized standards and national guidelines.
Digital health innovation leverages extended reality (XR), including virtual reality, augmented reality, and spatial computing, to enable healthcare professionals to make better-informed decisions. XR is transforming healthcare by offering immersive, interactive environments for medical research and clinical use. It helps professionals deliver more personalized, precise, and effective care. Additionally, XR allows researchers to visualize and engage with complex 3D data intuitively and immersively.
By application, the substance use disorder segment contributed the largest U.S. prescription digital therapeutics market share of 24% in 2025, as prescription digital therapeutics have the massive potential to increase patient access to SUD treatment. These therapeutics expand access to care, promote treatment compliance, and offer data-driven insights into the efficiency of particular therapeutic strategies or technology.
By device type, the smartphones segment contributed the largest market share of 52%, and is expected to grow at the fastest CAGR during the forecast period, as smartphones offer rapid access to targeted health information via electronic health records (EHRs) and varied health data apps, providing insights on medicines, health conditions, and health advice, allowing patients to have knowledge.
By end use, the patients segment held a significant share of 49% in the U.S. prescription digital therapeutics market, and is expected to grow at the fastest CAGR during the forecast period as advanced therapies are emerging to include digital technologies of various kinds, which enhance patient health, lower clinician workload, reduce expenses, lower health disparities, and increase access to needed treatments.
By technology, the cognitive behavioral therapy (CBT)-based segment contributed the largest market share of 33%, as Cognitive–behavioral therapy (CBT) supports patients in eliminating avoidant and safety-seeking behaviors, which prevent self-correction of defective beliefs, therefore enabling stress management to lower stress-associated disorders and improving mental health.
By workflow, the standalone digital therapeutics segment held a significant share of 42% in the U.S. prescription digital therapeutics market, as these technologies are evidence-based, clinically validated software applications used independently to manage, prevent, or treat health-related and behavioral disorders.
The four organizations in this market dominate the U.S. prescription digital therapeutics market. Meanwhile, Akili Interactive mainly focuses on cognitive dysfunction and neuron-associated conditions. Welldoc, their flagship product, BlueStar, is an inclusive digital therapeutic solution for diabetes that needs a prescription. Click Therapeutics, it develops and commercializes software-as-a-prescription (SaaxP) management targeting significant depressive disorder and substance use. Omada Health provides prescription and clinical-grade digital therapeutic programs for long-term disease management.
By Application
By Device Type
By Business Model
By End User
By Technology
By Prescription Type
By Distribution Channel
By Delivery Mode
